Synairgen (LON:SNG) Stock Price Down 16.2% – Here’s Why

Synairgen plc (LON:SNG) was down 16.2% during mid-day trading on Monday . The company traded as low as GBX 0.70 ($0.01) and last traded at GBX 0.70 ($0.01). Approximately 345,628 shares traded hands during mid-day trading, a decline of 77% from the average daily volume of 1,477,761 shares. The stock had previously closed at GBX 0.84 ($0.01).

Synairgen Stock Down 10.8 %

The company has a market capitalization of £8.29 million, a price-to-earnings ratio of -0.51 and a beta of -2.23. The business has a 50-day moving average price of GBX 1.69 and a 200-day moving average price of GBX 3.05.

Synairgen Company Profile

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.

Synairgen is conducting a double blind, placebo-controlled clinical trial in COVID-19 patients (SG016).